News & Events

All the latest news and events from PhoreMost

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration
7th January 2020

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim’s discovery programmes PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innov …

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs
21st June 2018

PhoreMost and o2h discovery collaborate to progress first-in-class drug discovery programs

PhoreMost completes $15M (£11M) Series-A round to enter drug discovery
15th May 2018

PhoreMost completes $15M (£11M) Series-A round to enter drug discovery

PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme
27th April 2018

PhoreMost and NeoPhore Receive Innovate UK Funding to Support Development of a Novel Small-Molecule Cancer Immunotherapy Programme

PhoreMost and Plexxikon collaborate to identify novel drug targets
16th April 2018

PhoreMost and Plexxikon collaborate to identify novel drug targets

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company
15th November 2017

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company

PhoreMost and Babraham Institute Awarded £0.6M Innovate UK Funding
15th June 2017

PhoreMost and Babraham Institute Awarded £0.6M Innovate UK Funding

Event

SLAS

25th to 26th January 2020